$1.40
-0.02-1.43%
At close: Jul 29, 6:21 PM EDT
$1.38
-0.02-1.43%
After Hours: 6:21 PM EDT
15 minutes delayed
Akebia Therapeutics reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Analyze the earnings history of Akebia Therapeutics using advanced sorting and filters.
Get Alert | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
AKBA | Akebia Therapeutics | -$0.06 | -$0.05 | — | — | $56.38M | $49.45M | — | — | 08/23/2024 | Get Alert |
AKBA | Akebia Therapeutics | -$0.14 | -$0.08 | -$0.09 | -12.50% | $40.13M | $46.34M | $32.61M | -29.64% | 05/09/2024 | Get Alert |
AKBA | Akebia Therapeutics | -$0.04 | -$0.04 | $0.00 | 100.00% | $55.78M | $55.39M | $56.20M | 1.46% | 03/14/2024 | Get Alert |
AKBA | Akebia Therapeutics | -$0.28 | -$0.08 | -$0.08 | 0.00% | $48.96M | $48.18M | $42.05M | -12.73% | 11/08/2023 | Get Alert |
AKBA | Akebia Therapeutics | $0.15 | -$0.02 | -$0.06 | -200.00% | $126.76M | $59.10M | $56.38M | -4.61% | 08/25/2023 | Get Alert |
AKBA | Akebia Therapeutics | -$0.35 | -$0.15 | -$0.14 | 6.67% | $61.70M | $46.68M | $40.13M | -14.04% | 05/08/2023 | Get Alert |
AKBA | Akebia Therapeutics | -$0.40 | -$0.19 | -$0.04 | 78.95% | $59.60M | $47.40M | $55.18M | 16.41% | 03/09/2023 | Get Alert |
AKBA | Akebia Therapeutics | -$0.34 | -$0.17 | -$0.28 | -64.71% | $48.76M | $48.88M | $48.96M | 0.17% | 11/03/2022 | Get Alert |
AKBA | Akebia Therapeutics | -$0.51 | -$0.31 | $0.23 | 174.19% | $52.91M | $49.73M | $126.76M | 154.89% | 08/04/2022 | Get Alert |
AKBA | Akebia Therapeutics | -$0.45 | -$0.29 | -$0.35 | -20.69% | $52.30M | — | $61.70M | — | 05/09/2022 | Get Alert |
AKBA | Akebia Therapeutics | -$0.60 | -$0.33 | -$0.40 | -21.21% | $56.70M | $50.80M | $59.60M | 17.33% | 03/01/2022 | Get Alert |
AKBA | Akebia Therapeutics | -$0.42 | -$0.32 | -$0.34 | -6.25% | $59.99M | $49.67M | $48.76M | -1.84% | 11/04/2021 | Get Alert |
AKBA | Akebia Therapeutics | -$0.44 | -$0.32 | -$0.51 | -59.38% | $90.14M | $52.88M | $52.91M | 0.06% | 08/05/2021 | Get Alert |
AKBA | Akebia Therapeutics | -$0.47 | -$0.36 | -$0.45 | -25.00% | $88.48M | $42.84M | $52.30M | 22.09% | 05/10/2021 | Get Alert |
AKBA | Akebia Therapeutics | -$0.79 | -$0.40 | -$0.60 | -50.00% | $69.56M | $51.16M | $56.70M | 10.83% | 02/25/2021 | Get Alert |
AKBA | Akebia Therapeutics | -$0.46 | -$0.17 | -$0.42 | -147.06% | $91.98M | $84.90M | $59.99M | -29.34% | 11/05/2020 | Get Alert |
AKBA | Akebia Therapeutics | -$0.25 | -$0.50 | -$0.44 | 12.00% | $100.80M | $74.18M | $90.14M | 21.52% | 08/10/2020 | Get Alert |
AKBA | Akebia Therapeutics | -$0.44 | -$0.62 | -$0.47 | 24.19% | $72.67M | $77.48M | $88.48M | 14.19% | 05/05/2020 | Get Alert |
AKBA | Akebia Therapeutics | -$0.76 | -$0.47 | -$0.79 | -68.09% | $59.85M | $93.15M | $69.56M | -25.33% | 03/10/2020 | Get Alert |
AKBA | Akebia Therapeutics | -$0.60 | -$0.43 | -$0.46 | -6.98% | $53.17M | $99.38M | $91.98M | -7.45% | 11/12/2019 | Get Alert |
AKBA | Akebia Therapeutics | -$0.60 | -$0.32 | -$0.25 | 21.88% | $48.79M | $91.13M | $100.80M | 10.61% | 08/08/2019 | Get Alert |
Fiscal Quarter End | Date Reported | Actual EPS | Estimated EPS | Surprise % |
---|---|---|---|---|
Mar 2024 | 2024-05-09 | $-0.09 | $-0.08 | -12.5 % |
Dec 2023 | 2024-03-14 | $0 | $-0.04 | 100.0 % |
Sep 2023 | 2023-11-08 | $-0.08 | $-0.08 | 0.00 % |
Jun 2023 | 2023-08-25 | $-0.06 | $-0.02 | -200.0 % |
Fiscal Quarter End | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
---|---|---|---|---|
Mar 2024 | 2024-05-09 | $32.61M | $46.34M | -29.6 % |
Dec 2023 | 2024-03-14 | $56.20M | $55.39M | 1.46 % |
Sep 2023 | 2023-11-08 | $42.05M | $48.18M | -12.7 % |
Jun 2023 | 2023-08-25 | $56.38M | $59.10M | -4.61 % |
Akebia Therapeutics (AKBA) is scheduled to report earnings on August 23, 2024. The last reported earnings were for reported on May 9, 2024 for Q1.
The Actual EPS was $-0.09, which missed the estimate of $-0.08.
The Actual Revenue was $32.6M, which missed the estimate of $46.3M.
Browse earnings estimates, EPS, and revenue on all stocks.